Achillion Pharmaceuticals, Inc. (ACHN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.26-0.10 (-1.20%)
At close: 4:00 PM EDT
People also watch:
FOLDACADARIACLDXARRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open8.32
Prev Close8.36
Bid8.20 x 200
Ask8.50 x 100
Day's Range8.20 - 8.43
52wk Range5.57 - 10.95
1y Target EstN/A
Market Cap1.13B
P/E Ratio (ttm)168.57
Beta2.26
Volume1,250,027
Avg Vol (3m)1,324,307
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube2 days ago

    ETF’s with exposure to Achillion Pharmaceuticals, Inc. : August 30, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Achillion Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to ACHN-US. Comparing the performance and risk of Achillion Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : August 29, 2016
    Capital Cube3 days ago

    Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : August 29, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Achillion Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Barrons.com14 days ago

    Gilead Sciences: Still Dominating Hepatitis C But…

    After surveying doctors on the preferred hepatitis-C treatments, Baird's Brian Skorney and Neena Bitritto-Garg contend that Gilead Sciences (GILD) is likely to maintain its dominance over AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) but in what appears to be a shrinking market. In conjunction with script trends, physicians indicate that the market for treatment-eligible, easily accessible Hep C patients is shrinking, but that Gilead's share of the shrinking pie is continuing to grow.